Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation

Vries, M.K. de; Brouwer, Elisabeth; Horst‐Bruinsma, Irene E. van der; Spoorenberg, A.; Denderen, J.C. van; Jamnitski, Anna; Nurmohamed, Michael T.; Dijkmans, Ben A. C.; Aarden, Lucien A.; Wolbink, Gertjan

doi:10.1136/ard.2009.109702

Cited by 84 publications

(49 citation statements)

References 10 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The formation of neutralising anti-drug antibodies (ADA) against the corresponding biologic or immune complexes that trigger proteolytic elimination in the reticuloendothelial system (RES) will cause increased clearance of a biologic. Infliximab, a chimeric IgG1κ monoclonal antibody (composed of human constant and murine variable regions) specific for human tumour necrosis factor-alpha (TNFα), was cleared more rapidly in patients who developed human anti-chimeric antibodies (HACAs) [17] . A decreased trough concentration with increasing immunogenicity was also reported for golimumab, a human IgG1κ monoclonal antibody specific for human tumour necrosis factor alpha (TNFα).…”

Section: Mechanistic Understanding Of the Pharmacokinetics Of Biologicsmentioning

confidence: 99%

Clinical pharmacology considerations in biologics development

Zhao

Ren

Wang³

2012

Acta Pharmacol Sin

View full text Add to dashboard Cite

Section: Mechanistic Understanding Of the Pharmacokinetics Of Biologicsmentioning

confidence: 99%

Clinical pharmacology considerations in biologics development

Zhao

Ren

Wang³

2012

Acta Pharmacol Sin

View full text Add to dashboard Cite

“…По данным литерату-ры, это может быть обусловлено снижением концентра-ции препарата в сыворотке в результате образования АТ к нему. Позитивные по АТ к ИНФ и АДА больные АС ре-же отвечают на терапию, чем больные с отсутствием дан-ных АТ [19].…”

Section: Discussionunclassified

Investigation of a Role of the Immunogenicity of Infliximab in the Therapy of Ankylosing Spondylitis

Румянцева¹,

Бочкова²,

Урумова³

et al. 2016

rsp

View full text Add to dashboard Cite

“…Recent studies with AS patients have tried to analyze the relationship between ATI development and clinical efficacy of infliximab [52] or adalimumab [53]. In contrast, no antibodies have been found to develop under treatment with etanercept [50].…”

Section: Autoimmunitymentioning

confidence: 98%

Biologic Therapies for Spondyloarthritis: What Is New?

Baraliakos

Braun

2012

Curr Rheumatol Rep

View full text Add to dashboard Cite

The course of axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS), is strongly influenced by the degree of disease activity over time, which is mainly based on inflammation, and by the impairment of function, which is based on structural damage-mainly, new bone formation-and inflammation. In AS, nonsteroidal anti-inflammatory agents are currently recommended as the first choice of medical therapy, and there is also a clear role for regular exercise and physiotherapy in order to preserve and prevent loss of spinal mobility. For patients who have insufficiently responded to conventional medications, there are now four biologics approved for the treatment of patients with active AS in many countries, all directed against TNFα: infliximab, etanercept, adalimumab, and golimumab; studies with certolizumab are currently ongoing. Several studies with patients classified as nonradiographic axSpA have also shown a good response to TNF blockers; in patients with early disease and high CRP levels, the response rates were even better. Long-term studies with TNF blockers have shown declining retention rates over time but sustained clinical efficacy in the patients who remained on treatment. States of drug-free remission are rarely reached and only for relatively short periods of time. More studies including magnetic resonance imaging (MRI) are needed to further examine the lack of effect of anti-TNF treatment on radiographic progression in the axial skeleton. Whether the effect of an early intervention with biologics will prevent the development of bone growth in patients with nonradiographic axial SpA remains to be seen. Biologics other than TNF blockers are currently not recommended for the treatment of patients with axSpA, because of insufficient evidence of clinically relevant efficacy. The anti-IL-17a antibody secukinumab may be efficacious, on the basis of a proof-of-concept trial. Finally, first data on biosimilars of TNF blockers have recently been presented.

show abstract

Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation

Cited by 84 publications

References 10 publications

Clinical pharmacology considerations in biologics development

Clinical pharmacology considerations in biologics development

Investigation of a Role of the Immunogenicity of Infliximab in the Therapy of Ankylosing Spondylitis

Biologic Therapies for Spondyloarthritis: What Is New?

Contact Info

Product

Resources

About